Cargando…
2648. Taming the Cytokine Storm: Baricitinib versus Tocilizumab for COVID-19 Hyperinflammation
BACKGROUND: Baricitinib and tocilizumab are potent immunomodulators that can reduce mortality in severe and critical COVID-19. The objective of this study was to compare the outcomes of patients with COVID-19 who were treated with either baricitinib or tocilizumab. METHODS: This was a single-center,...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Oxford University Press
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10679165/ http://dx.doi.org/10.1093/ofid/ofad500.2260 |